Effect of Probiotic on Gut Microbiota in Young Children With Functional Constipation

This study was a 28-day, open-label, randomized controlled trial involving infants and toddlers diagnosed with functional constipation. Participants were randomized to receive either Bifidobacterium longum subsp. longum Dipro-X, lactulose, or a combination of both. The primary clinical outcomes assessed were bowel movement frequency, stool consistency, and defecation difficulty. To investigate potential mechanisms, stool samples were collected pre- and post-intervention for metagenomics sequencing to analyze changes in gut microbiota composition and identify specific bacterial taxa associated with clinical improvements.

Study Overview

• Status: Completed
• Conditions: Functional Constipation in Children
• Intervention / Treatment: Dietary supplement: Probiotic; Dietary supplement: Lactulose Oral Liquid Product; Dietary supplement: probiotic + lactulose

Detailed Description

Functional constipation is a prevalent chronic gastrointestinal disorder with significant implications for pediatric health. Within the first year of life, many infants are affected, a figure that rises to over 10% annually. This condition not only diminishes the quality of life for infants and toddlers but also contributes to substantial healthcare costs. Early intervention is widely recognized as critical for improving treatment outcomes, underscoring the need for effective therapeutic strategies.

Growing evidence indicates that intestinal microbiota dysbiosis plays a key role in the pathogenesis of functional constipation. Studies have consistently reported reduced abundances of beneficial bacteria such as Lactobacillus and Bifidobacterium in affected individuals compared to healthy controls. These findings have spurred interest in microbiota-targeted interventions, particularly the use of Bifidobacterium, for managing constipation. Although current evidence-based guidelines do not uniformly recommend probiotics for infant constipation due to limited clinical data, their potential to restore microbial balance remains promising. Advances in genomic technologies have enabled more detailed investigations into strain-specific mechanisms, shifts in signature microorganisms, and associated symptomatic improvements, findings that may help bridge existing evidence gaps. While preclinical studies, such as those involving murine models, have shown that Bifidobacterium longum can alleviate constipation by enhancing intestinal barrier function, clinical evidence in pediatric populations remains scarce.

To address this, the present study was conducted as a randomized, open-label, three-arm controlled clinical trial. It aimed to evaluate the efficacy of Bifidobacterium longum subsp. longum Dipro-X, lactulose, and their combination in infants and toddlers with functional constipation. The study specifically assessed the intervention's effects on clinical symptoms, including defecation frequency and stool characteristics, and explored correlations between gut microbiota changes and symptom improvement. The results are intended to support the development of evidence-based, targeted microbial interventions for functional constipation in early childhood.

• Study Type: Interventional
• Enrollment (Actual): 84
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Shanghai, China
    • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
• Malaysia
  • Pulau Pinang, Malaysia
    • Universiti Sains Malaysia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• According to the diagnostic criteria of Rome IV, the following symptoms include at least 2 and last for at least 1 month:

  1. Defecation <= 2 times per week;
  2. have a history of fecal retention;
  3. There is a history of pain or difficulty in defecation;
  4. There is a history of expelling large pieces of feces;
  5. There is a large fecal mass in the rectum. At least 1 episode of incontinence per week after self-control of bowel movements; passing large pieces of stool that may clog the toilet;
• Term infants, gestational age from 37 to 42 weeks;
• Birth weight between 2500 - 4000g;
• 0-3 years old;
• Parents voluntarily defer major changes in infant feeding practices;
• Parents are willing and able to fill in diaries and questionnaires

Exclusion Criteria:

• Chronic diseases or major medical problems;
• Gastrointestinal organic diseases;
• Growth retardation;
• The mother or child of the breastfeeding child used antibiotics within 4 weeks prior to enrollment;
• Infants (in formula and/or supplements) or their mothers used probiotics within 2 weeks before randomization and during the trial;
• Has participated in other clinical trials;
• Food allergies cause constipation (such as milk, eggs and other foods)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Probiotic; Daily 6-drops of Bifidobacterium longum subsp. longum Dipro-X in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1 × 10^9 CFU/day)	Dietary supplement: Probiotic; Daily 6-drops of Bifidobacterium longum subsp. longum Dipro-X in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1× 10^9 CFU/day)
Active Comparator: Lactulose; Lactulose liquid (each 1ml contains 0.667g lactulose) 5ml/time, once a day	Dietary supplement: Lactulose Oral Liquid Product; Lactulose liquid (each 1ml contains 0.667g lactulose) 5ml/time, once a day
Active Comparator: Probiotic+Lactulose; Daily 6-drops of Bifidobacterium longum subsp. longum Dipro-X in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1 × 10^9 CFU/day), plus Lactulose liquid (each 1ml contains 0.667g lactulose) 5ml/time, once a day	Dietary supplement: probiotic + lactulose; Daily 6-drops of Bifidobacterium longum subsp. longum Dipro-X in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1× 10^9 CFU/day), plus Lactulose liquid (each 1ml contains 0.667g lactulose) 5ml/time, once a day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Defecation difficulty in young children upon administration of probiotic, lactulose or their combinations as assessed via Visual Anologue Scale (VAS)	Differences in defecation difficulty in young children upon administration of probiotic, lactulose or their combinations, where higher scores indicate greater defecation difficulty (worse outcome).	Day-0, day-14, day-28
Bowel movement frequency in young children upon administration of probiotic, lactulose or their combinations as assessed via patients' diary	Differences in bowel movement frequency in young children upon administration of probiotic, lactulose or their combinations	Day-0, day-28
Bristol stool score in young children upon administration of probiotic, lactulose or their combinations as assessed via Bristol stool chart	Differences in Bristol stool score in young children upon administration of probiotic, lactulose or their combinations, where lower scores indicate constipation-like outcomes and higher scores indicate diarrea-like outcomes	Day-0, day-14, day-28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Microbiota profiles of fecal samples in young children upon administration of probiotic, lactulose or their combinations as assessed via metagenomics sequencing	Differences in microbiota profiles in fecal sample of young children upon administration probiotic, lactulose or their combinations	Day-0, day-28

Collaborators and Investigators

• Sponsor: Min-Tze LIONG
• Collaborators: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Investigators: Principal Investigator: Yi Feng, MD., Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Study record dates

Study Major Dates

• Study Start (Actual): June 10, 2020
• Primary Completion (Actual): February 28, 2026
• Study Completion (Actual): February 28, 2026

Study Registration Dates

• First Submitted: January 13, 2026
• First Submitted That Met QC Criteria: January 13, 2026
• First Posted (Actual): January 22, 2026

Study Record Updates

• Last Update Posted (Actual): April 7, 2026
• Last Update Submitted That Met QC Criteria: March 31, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: probiotic; infants; toddlers; functional constipation; Bifidobacterium longum subsp. longum Dipro-X
• Additional Relevant MeSH Terms: Dietary Supplements; Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages; Carbohydrates; Polysaccharides; Disaccharides; Oligosaccharides; Sugars; Lactulose; Probiotics
• Other Study ID Numbers: XHEC-C-2018-027

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No